RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...

Please provide your email address to receive an email when new articles are posted on . Gaps in access remain, though, as almost half of patients did not receive next-generation sequencing. “These ...

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new ...

HER2 mutations involve genetic alterations, while HER2 expression refers to protein overexpression, both impacting NSCLC treatment strategies. Fam-trastuzumab deruxtecan-nxki and ado-trastuzumab ...

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted ...

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced results from a study, where Cellworks' biosimulation ...

Metastatic non-small cell lung cancer (NSCLC) can affect every part of your life: your health, your relationships, and even your finances. Fortunately, you’re not on this journey alone. An entire team ...

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest ...

Sample management algorithm for average-risk patients. A. Resection suggested over stereotactic body radiotherapy or ablative techniques. B. Resection by a board-certified thoracic surgeon suggested.